文献速递冠心病血脂与心血管预防

JCAD通过PI3K/Akt调控促进动脉血栓形成:一项转化研究

JCAD promotes arterial thrombosis through PI3K/Akt modulation: a translational study.
PubMed 文献 · Eur Heart J · 2023-01-01

本研究探讨JCAD在动脉血栓形成中的作用。Jcad-/-小鼠光化学诱导内皮损伤后颈动脉闭塞时间延迟,凝血 cascade 激活减少且纤溶增强;体外HAECs中JCAD沉默通过PI3K/Akt通路抑制TF和PAI-1表达;STEMI患者血浆JCAD高于慢性冠脉综合征患者,且与TF、PAI-1正相关。

要点

  • JCAD敲除小鼠动脉血栓形成延迟,凝血激活减少、纤溶增强。
  • JCAD沉默通过PI3K/Akt通路抑制内皮细胞TF和PAI-1表达。
  • STEMI患者血浆JCAD升高且与TF、PAI-1正相关。

核心结论

  • JCAD通过调控凝血和纤溶促进动脉血栓形成,可能成为动脉血栓治疗靶点。

研究设计与样本

  • Jcad-/-小鼠行光化学诱导内皮损伤触发动脉血栓形成。
  • 原代人主动脉内皮细胞(HAECs)转染JCAD siRNA、LATS2 siRNA或对照siRNA进行体外实验。
  • 检测慢性冠脉综合征或ST段抬高型心肌梗死(STEMI)患者血浆JCAD。

主要发现

  • Jcad-/-小鼠颈动脉闭塞时间延迟,提示血栓形成性降低。
  • Jcad-/-小鼠凝血 cascade 激活减少(组织因子TF表达和活性降低)。
  • Jcad-/-小鼠纤溶增强(血栓栓塞事件和D-二聚体水平升高,血管PAI-1表达降低)。
  • 体外JCAD沉默抑制HAECs中TF和PAI-1表达,并增加LATS2激酶水平。
  • JCAD沉默增加PI3K/Akt活化,PI3K/Akt抑制剂渥曼青霉素阻止其对TF和PAI-1的影响,且JCAD与Akt直接相互作用。

关键数值与推荐

  • Jcad-/-小鼠颈动脉闭塞时间延迟,凝血 cascade 激活减少(TF表达和活性降低),纤溶增强(血栓栓塞事件和D-二聚体水平升高,血管PAI-1表达降低)。
  • JCAD沉默的HAECs中TF和PAI-1表达受抑,LATS2激酶水平升高,PI3K/Akt活化增加。
  • PI3K/Akt抑制剂渥曼青霉素阻止JCAD沉默对TF和PAI-1的影响。
  • JCAD与Akt存在直接相互作用。
  • STEMI患者血浆JCAD高于慢性冠脉综合征患者,且与TF和PAI-1水平正相关。

临床怎么用

  • JCAD可能作为动脉血栓形成的潜在治疗靶点,但尚需临床验证。

局限性

  • 研究主要为动物和体外实验,临床数据仅观察性关联,未验证因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Variants of the junctional cadherin 5 associated (JCAD) locus associate with acute coronary syndromes. JCAD promotes experimental atherosclerosis through the large tumor suppressor kinase 2 (LATS2)/Hippo pathway. This study investigates the role of JCAD in arterial thrombosis. METHODS AND RESULTS: JCAD knockout (Jcad-/-) mice underwent photochemically induced endothelial injury to trigger arterial thrombosis. Primary human aortic endothelial cells (HAECs) treated with JCAD small interfering RNA (siJCAD), LATS2 small interfering RNA (siLATS2) or control siRNA (siSCR) were employed for in vitro assays. Plasma JCAD was measured in patients with chronic coronary syndrome or ST-elevation myocardial infarction (STEMI). Jcad-/- mice displayed reduced thrombogenicity as reflected by delayed time to carotid occlusion. Mechanisms include reduced activation of the coagulation cascade [reduced tissue factor (TF) expression and activity] and increased fibrinolysis [higher thrombus embolization episodes and D-dimer levels, reduced vascular plasminogen activator inhibitor (PAI)-1 expression]. In vitro, JCAD silencing inhibited TF and PAI-1 expression in HAECs. JCAD-silenced HAECs (siJCAD) displayed increased levels of LATS2 kinase. Yet, double JCAD and LATS2 silencing did not restore the control phenotype. si-JCAD HAECs showed increased levels of phosphoinositide 3-kinases (PI3K)/ proteinkinase B (Akt) activation, known to downregulate procoagulant expression. The PI3K/Akt pathway inhibitor-wortmannin-prevented the effect of JCAD silencing on TF and PAI-1, indicating a causative role. Also, co-immunoprecipitation unveiled a direct interaction between JCAD and Akt. Confirming in vitro findings, PI3K/Akt and P-yes-associated protein levels were higher in Jcad-/- animals. Lastly, as compared with chronic coronary syndrome, STEMI patients showed higher plasma JCAD, which notably correlated positively with both TF and PAI-1 levels. CONCLUSIONS: JCAD promotes arterial thrombosis by modulating coagulation and fibrinolysis. Herein, reported translational data suggest JCAD as a potential therapeutic target for atherothrombosis.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Liberale L, Puspitasari YM, Ministrini S, et al. JCAD promotes arterial thrombosis through PI3K/Akt modulation: a translational study. Eur Heart J. 2023. PMID: 36469488. doi:10.1093/eurheartj/ehac641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。